Radiopharmaceuticals for the Visualization of Infectious and Inflammatory Lesions

Authors: Ercan, M.T.; Kostakoglu, L.

Source: Current Pharmaceutical Design, Volume 6, Number 11, 1 July 2000 , pp. 1159-1177(19)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Many radiopharmaceuticals have been introduced for the scintigraphic demonstration of infectious and inflammatory lesions and some of them are currently in clinical use. They can be classified into two major categories according to their specificity. Specific radiopharmaceuticals include in vitro labeled leukocytes, radio-labelled monoclonal antibodies, and receptor specific small proteins and peptides. Nonspecific radiopharmaceuticals include radiolabelled nanocolloids, liposomes, macromolecules such as human immunoglobulin, dextran and human serum albumin, various small molecules and ions. In this review article radiopharmaceuticals in their respective groups are discussed as to the efficacy, and other parameters such as the physical characteristics of the radionuclides used, radiochemistry involved, availability, cost and biodistribution, emphasizing recent developments.

Keywords: Radiopharmaceuticals; Infectious; Inflammatory Lesions; Labelling inflammation imaging agents; Radiolabelled leukocytes; Radiocolloids; Phagocytic labelling; Monoclonal antibodies; Antibodies against granulocyte antigens; Lymphocyte antigens; Interleukin; Tuftsin antagonists; Platelet factor; Chemotactic peptides; Somatostatin analogues; Radiolabelled J001X; Klebsiella pneumoniae; Neuroendocrine; Nonspecific radiopharmaceuticals; Dextran; Pentavalent DMSA; Cysteine; Glutathione; Streptaidin